Last reviewed · How we verify
NCT03791450
Investigation of Pancreaticoduodenectomy
trial in Pancreaticoduodenectomy in 10,085 participants. Completed in 1 August 2019.
1 August 2019
Quick facts
| Lead sponsor | Tongji Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10,085 |
| Start date | 1 March 2019 |
| Primary completion | 1 August 2019 |
| Estimated completion | 1 August 2019 |
| Sites | 1 location across China |
Conditions studied
- Pancreaticoduodenectomy — all drugs for Pancreaticoduodenectomy →
Sponsor
Tongji Hospital
Who can join
Eligibility, any sex, with Pancreaticoduodenectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators intend to conduct a multicentre, big-sample, retrospective study to analysis the surgery results of pancreaticoduodenectomy and compare the different suture technique.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03791450
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreaticoduodenectomy
Currently open trials in the same condition.
- NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
- NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting
- NCT07412301 — The Effect of Celiac Axis Stenosis on Morbidity After Pancreatoduodenectomy - A Prospective Study · active not recruiting
- NCT06322680 — Impact of External Drainage of the Main Pancreatic Duct and Common Bile Duct on Pancreatic Fistula Following Pancreatico · NA · recruiting
- NCT03785743 — Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma · NA · recruiting
Other Tongji Hospital trials
Trials by the same sponsor.
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
- NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
- NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03791450 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
- Last refreshed: 4 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03791450.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing